Striving for Operational Excellence in the Pharmaceutical Industry

Towards Deep Structures
Erscheinungsjahr 2026
ISBN: 978-3-032-26286-8
Verlag: Springer Nature Switzerland AG

Buch, Englisch, 359 Seiten, Format (B × H): 155 mm x 235 mm

Reihe: Future of Business and Finance

Building on the foundation laid by Friedli et al. (2013, Springer) in "Leading Pharmaceutical Operational Excellence," this book presents an evolved perspective on Operational Excellence in the Pharmaceutical Industry. It offers an update on two decades of research and provides deep insights into current practices. This essential guide supports practitioners on their journey towards sustainable implementation of Operational Excellence, featuring the latest developments, databased and qualitative findings. Written by University of St.Gallen (Switzerland) academics and industry leaders, including experts from prominent global pharmaceutical companies and specialized research scholars, it blends practical experience with theoretical knowledge, making it an invaluable resource for professionals seeking to enhance their operational strategies.

Ideal for industry professionals, managers, and researchers, this book is an invaluable resource for those seeking to enhance their operational strategies.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Friedli, Thomas

Cafone, Jim

Bernasconi, Matteo

Klinkner, Fabian

Fachgebiete

• Geowissenschaften Umweltwissenschaften Nachhaltigkeit
• Wirtschaftswissenschaften Betriebswirtschaft Bereichsspezifisches Management Betriebliches Energie- und Umweltmanagement
• Wirtschaftswissenschaften Wirtschaftssektoren & Branchen Wirtschaftssektoren & Branchen: Allgemeines
• Wirtschaftswissenschaften Betriebswirtschaft Management

Inhaltsverzeichnis

Part 1: The Rise of OPEX in the Pharmaceutical Industry.- OPEX 2026: A Definition.- Triggers and Forces: Past and Current Situation.- Reassessing the State of Pharmaceutical OPEX: A (R)evolution in Figures.- Reinventing OPEX In Pfizer: Why and how we did it.- Part 2: Learnings from two Decades of OPEX Research.- OPEX Programs: The Phenomenon.- OPEX Programs: Measuring and Improving Results.- OPEX Programs: Network-level Rollout.- Towards a Better Understanding of What Really Makes the Difference Lead it or Leave it.- OPEX and Quality: One Path to Excellence Reconciling OPEX and Digital.- Continuous Improvement in Regulated Industries.- Quality First: Regulatory and Industry Collaborations in Pharmaceutical Manufacturing.- Part 3: How it Looks in the Field.- Culture as the Engine of Patient-Focused Excellence Linking Culture and Behaviors to the Essence of Work.- OPEX in Pfizer Global Supply (PGS).- OPEX Needs an Upgrade: Reinventing OPEX in the Age of Digital/AI OPEX Leadership Lessons.- Beyond Distance, Towards Excellence: Leading OPEX Programs in Dispersed Teams.- “Execution Excellence” Demonstrated by Boehringer Ingelheim BioPharma RCV – Vienna/Austria.- OEE Improvement in Sterile Operations of Dechra Pharmaceuticals.- Data Analytics as an Enabler of Quality and OPEX in the Pharmaceutical Supply Chain.- Unlocking Business Value Through Quality Management System Transformation.- The 6 Traits of Quality Business Leadership.- OPEX & System Engineering – Advancing Healthcare through the End-to-End Supply Chain Management.- Part 4: Conclusions from the Book.- What Are Deep Structures?.- Towards Deep Structures.

Über Autor(innen)

Thomas Friedli is Director of the Institute of Production and Supply Chain Management and Professor for production management at the University of St.Gallen (Switzerland). His main research interests are in the field of managing global production, operational excellence, and industrial services.

Jim Cafone, Senior Vice President, Global Supply Chain at Pfizer Inc., has been with the company since 2010. He oversees global demand forecasting, supply planning, logistics, and inventory management. Previously, he held various roles at Wyeth Pharmaceuticals, including Vice President positions. Jim holds degrees in Industrial Engineering, Mechanical Engineering, and Technology Management.

Matteo Bernasconi is a senior data scientist at AbbVie. He holds a PhD degree in Management from the University of St.Gallen (Switzerland) and has experience in working on research projects for the U.S. Food and Drug Administration. His research has been focusing on preventive quality risk management and data-driven decision-making.

Fabian Klinkner worked as a Research Associate and Post Doc at the Institute of Technology Management (ITEM-HSG), University of St.Gallen (Switzerland) coordinating the Operational Excellence team. He holds a Ph.D. from the University of St.Gallen as well as an M.Sc. in Industrial Engineering and Management from Karlsruhe Institute of Technology (KIT, Germany).